HFHussam Fallatah

Hussam Fallatah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hussam Fallatah has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Secretory IgA–Gut Microbiota Crosstalk in Mucosal Immunity

    by Faisal S. Alagrafi, Samiyah Al-Khaldi, Mohammad N. Alkhrayef, Ibtihal S. Alduhaymi, Musaad A. Altammami, Hala A. Alamari, Monira Alshehri, Hind J. Althagafi, Hussam M. Fallatah, Essam J. Alyamani, et al.

    Secretory immunoglobulin A (SIgA) represents the most abundant antibody isotype at mucosal surfaces and plays a central role in maintaining intestinal immune homeostasis. In addition to its classical function in immune exclusion of pathogens, SIgA actively shapes the composition, spatial organization, and functional behavior of the gut microbiota, thereby contributing to a dynamic and reciprocal host–microbe relationship. Increasing evidence highlights that crosstalk between SIgA and the gut microbiota is not merely protective but also regulatory, influencing immune tolerance, barrier integrity, and inflammatory balance within the intestinal mucosa. This review provides a comprehensive overview of the molecular and immunological mechanisms underlying SIgA–microbiota interactions in mucosal immunity. We discuss the processes governing SIgA induction, class switching, and antigen specificity, as well as the mechanisms by which SIgA selectively coats commensal and pathogenic microorganisms. Emphasis is placed on how SIgA-mediated immune modulation shapes microbial ecology, limits immune overactivation, and maintains long-term mucosal homeostasis. Moreover, the review describes the role of dysregulation in SIgA–microbiota interactions in immune-mediated and inflammatory diseases, as well as the emerging translational perspectives. This includes the potential of SIgA-targeted strategies to modulate the gut microbiota for therapeutic benefit. By integrating mechanistic insights with clinical relevance, this review highlights SIgA–microbiota interactions at the intersection of mucosal immunology and emerging immunotherapeutic opportunities.

  • Open Access

    Point-of-Care Diagnostic Technologies for Antimicrobial Resistance: Principles, Platforms, Clinical Impact, and Future Directions

    by Nahed N. Mahrous, Mohannad M. Fallatah, Rawan A. Fitaihi, Hala Aldahshan, Areej A. Alhhazmi, Samiyah Al-Khaldi, Hussam Fallatah, Abdulmajeed A. Althobaiti, Abdulaziz Saleh Alkhoshaiban, Jawaher Alguraini, et al.

    Antimicrobial resistance (AMR) is an ever-growing threat to global healthcare. It is largely driven by delayed or inadequate pathogen identification and antimicrobial susceptibility testing in routine clinical workflows. By the time the clinician receives results to guide treatment from traditional culture-based diagnostics, several days may have elapsed, leading to the use and potential over-prescription of broad-spectrum antibiotics and the development of resistant pathogens. A rapid and clinically actionable diagnostic approach at the clinical point of care (POC) may help address this gap. This review examines current and emerging POC diagnostic technologies for AMR and outlines the fundamental principles and mechanistic classifications of POC diagnostic technologies. These include phenotypic, genotypic, immunological, and biosensor-based approaches. A critical overview of key technological platforms, including rapid phenotypic antimicrobial susceptibility testing (AST), microfluidics and isothermal nucleic acid amplification (e.g., LAMP and RPA), CRISPR-based diagnostics, nanomaterial-enhanced biosensors, and mobile-integrated systems is provided. The impact of POC diagnostics on antimicrobial stewardship, time to appropriate therapy, and patient outcomes in primary care settings, hospitals, intensive care units, and resource-limited settings is presented and discussed. In addition to clinical implementation challenges, this review considers the issues of analytical performance, workflow, regulatory pathways, cost, and implementation readiness. In addition, it outlines key trends regarding digital integration, surveillance, workforce training, and policy frameworks. Overall, the review outlines the role of POC diagnostics in enhancing antimicrobial response surveillance and the global fight against AMR. Among emerging platforms, rapid phenotypic AST, microfluidic and isothermal-based assays, CRISPR-based diagnostics, and integrated biosensor systems show the greatest potential for near-term clinical impact; however, widespread implementation remains constrained by challenges related to clinical validation, cost, workflow integration, and alignment with antimicrobial stewardship frameworks.